

# SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\*

## 上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司)

(Stock code: 1877) (股份代號 : 1877)

### NOTIFICATION LETTER 通知信函

29 September 2022

Dear non-registered shareholder,

Shanghai Junshi Biosciences Co., Ltd.\* (the "Company") Notice of Publication of the 2022 Interim Report ("Current Corporate Communication")

The English and Chinese versions of the Company's Current Corporate Communication are available on the websites of the Company (www.junshipharma.com) and The Stock Exchange of Hong Kong Limited (www.hkexnews.hk).

If you want to receive a printed version of the Current Corporate Communication, please complete and sign the Request Form on the reverse side and return it to the H share registrar of the Company, Tricor Investor Services Limited (the "H Share Registrar") by using the mailing label at the bottom of the Request Form (no stamp is required if posted in Hong Kong; otherwise, please affix an appropriate stamp). The address of the H Share Registrar is 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. You may also send an email with a scanned copy of the completed and signed Request Form to 1877-ecom@hk.tricorglobal.com. The Request Form may also be downloaded from the websites of the Company (www.junshipharma.com) and The Stock Exchange of Hong Kong Limited (www.hkexnews.hk).

Should you have any queries relating to this letter, please contact the H Share Registrar at (852) 2980 1333 during business hours from 9:00 a.m. to 5:00 p.m. from Monday to Friday, excluding Hong Kong public holidays.

Yours faithfully
By order of the Board
Shanghai Junshi Biosciences Co., Ltd.\*
Mr. Xiong Jun
Chairman

Note: This letter is addressed to non-registered shareholder ("non-registered shareholder" means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive Corporate Communications). If you have sold or transferred your shares in the Company, please disregard this letter and the Request Form on the reverse side.

\* For identification purpose only.

各位非登記股東:

#### 上海君實生物醫藥科技股份有限公司(「本公司」) 2022年中期報告(「是次公司通訊」)之發佈通知

本公司的是次公司通訊之英文及中文版本已上載於本公司網站(www.junshipharma.com)及香港聯合交易所有限公司披露易網站(www.hkexnews.hk)。

倘 閣下欲收取是次公司通訊之印刷本,請填妥及簽署在本函背面的申請表格,並使用申請表格底部之郵寄標籤寄回本公司之H股股份過戶登記處卓佳證券登記有限公司(「H股股份過戶登記處」)(如在香港投寄,毋須貼上郵票;否則,請貼上適當的郵票)。H股股份過戶登記處地址為香港夏慤道16號遠東金融中心17樓。 閣下亦可把已填妥及簽署之申請表格的掃描副本電郵至1877-ecom@hk.tricorglobal.com。申請表格亦可於本公司網站(www.junshipharma.com)及香港聯合交易所有限公司披露易網站(www.hkexnews.hk)下載。

倘 閣下對本函內容有任何疑問,請於辦公時間內,即星期一至星期五(香港公眾假期除外)上午9時正至下午5時正致電H股股份過戶登記處之電話熱線(852)29801333查詢。

此致

承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 *主席* 謹啟

2022年9月29日

附註: 此函件乃向非登記股東(「非登記股東」指其股份存放於中央結算及交收系統的人士或公司,透過香港中央結算有限公司不時向本公司 發出通知,表示欲收到公司通訊)發出。倘 閣下已經出售或轉讓所持有之本公司股份,則毋須理會本函及背面的申請表格。

## REQUEST FORM 申請表格

Shanghai Junshi Biosciences Co., Ltd.\* (the "Company")

(Please mark a "/" in ONLY ONE of the following hoves)

(Stock Code: 1877)

c/o Tricor Investor Services Limited

17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong

致: 上海君實生物醫藥科技股份有限公司(「本公司」)

(股份代號:1877)

經卓佳證券登記有限公司

香港夏慤道16號遠東金融中心17樓

I/We would like to receive the current and all future Corporate Communications of the Company ("Corporate Communications") in the manner as indicated below:

本人/我們希望以下列方式收取 貴公司之是次及所有日後公司通訊(「公司通訊」):

(請從下列選擇中,僅在其中一個空格內劃上「✔」號)		
	to receive the <b>printed English version</b> of the current and all future Corporate Comm 僅收取是次及所有日後公司通訊的 <b>英文印刷本;或</b>	nunications ONLY; OR
	to receive the <b>printed Chinese version</b> of the current and all future Corporate Comm僅收取是次及所有日後公司通訊的 <b>中文印刷本;或</b>	nunications ONLY; OR
	to receive both the <b>printed English and Chinese versions</b> of the current and all future Corporate Communications. 同時收取是次及所有日後公司通訊的 <b>英文及中文印刷本</b> 。	
Non-re	nistered shareholder's full name 非発記股車全名:	Signature 答复:

(Please use BLOCK LETTERS 請用正楷填寫)

Address 地址: Contact telephone number 聯絡電話號碼: Date 日期:

Notes 附註:

- Please complete all your details clearly. 請 閣下清楚填妥所有資料。
- This letter is addressed to Non-registered shareholders of H shares ("Non-registered shareholder of H shares" means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive Corporate
- 此函件乃向非登記H股股東(「非登記H股股東」指其股份存放於中央結算及交收系統的人士或公司,透過香港中央結算有限公司不時向本公司發出通知,希望收到公司通訊)發出。
- 此時件刊向非登記出放股東 () 非登記出放放東] 指具股份存放於中央結算及文帜系統的人士或公司,透過香港中央結算有限公司不時向本公司發出週知,希望収到公司週訊) 發出。
  Any form with more than one box marked (4), with no signature or otherwise incorrectly completed will be void.
  如在本表格作出超過一項選擇、或未有作出選擇、或未有簽署、或在其他方面讲寫不正確,則本表格將會作廢。

  The above instruction will apply to the current and all future Corporate Communications to be sent to you until you notify to the Company c/o Tricor Investor Services Limited to the contrary or unless you have at anytime ceased to have holdings in the Company.
  上述指示適用於發送予 関下之是次及所有日後公司通訊、直至 関下通知本公司之H股股份過戶登記處卓佳證券登記有限公司另外之安排或任何時候停止持有本公司的股份。
  For the avoidance of doubt, the Company does not accept any special instructions written on this Request Form.
  為免存疑,任何在本申請表格上的額外手寫指示,本公司將不予處理。
- Corporate Communication(s) refer to any document issued or to be issued by the Company for the information or action of holders of any of the Company's securities, including but not limited to: (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where
- applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a proxy form; and (g) a reply slip. 公司通訊指由本公司發出或將予發出以供本公司任何證券的持有人參照或採取行動的任何文件,其中包括但不限於:(a)董事會報告、年度賬目連同核數師報告及財務摘要報告 (如適用);(b)中期報告及中期摘要報告 (如適用);(c)會議通告;(d)上市文件;(e)通函;(f)代表委任表格;及(g)回執。
- For identification purpose only 僅供識別之用

MAILING LABEL 郵寄標籤

**Tricor Investor Services Limited** Freepost No. 10 GPO Hong Kong 卓佳證券登記有限公司 簡便回郵號碼10 GPO 香港 上海君實生物醫藥科技股份有限公司 (1877)

Please cut the mailing label and stick it on an envelope to return this Reply Form to us.

No postage stamp is necessary if posted in Hong Kong. 閣下寄回此回條時,請將郵寄標籤剪貼於信封上。 如在香港投寄,毋須貼上郵票。

